InhibitorSelect EGFR Signaling Pathway Inhibitor Panel

A panel containing 13 potent and selective inhibitors useful for the study of EGFR signaling pathway. This panel contains the following inhibitors and 15 ml anhydrous DMSO for reconstitution:

A panel containing 13 potent and selective inhibitors useful for the study of EGFR signaling pathway. This panel contains the following inhibitors: 1 mg of Akt Inhibitor VIII, Isozyme-Selective, Akt-1/2 (Cat. No. 124018); 1 mg of PD 153035 (Cat. No. 234490); 1 mg of EGFR Inhibitor (Cat. No. 324674); 5 mg of Et-18-OCH₃ (Cat. No. 341207); 5 mg of JNK Inhibitor II (Cat. No. 420119); 5 mg of LY 294002 (Cat. N0. 440202); 5 mg of PD 98059 (Cat. No. 513000); 1 mg of PD 168393 (Cat. No. 513033); 1 mg of PP2 (Cat. No. 529573); 100 µg of Rapamycin (Cat. No. 553210); 1 mg of SB 203580 (Cat. No. 559389); 5 mg of AG 490 (Cat. No. 658401) and 1 mg of ZM 336372 (Cat. No. 692000). Also provided is 15 ml of anhydrous DMSO. Supplied with a data sheet.

The InhibitorSelect EGFR Signaling Pathway Inhibitor Panel controls the biological activity of InhibitorSelect.

InhibitorSelect EGFR Signaling Pathway Inhibitor Panel contains 13 potent and selective inhibitors useful for the study of EGFR signaling pathway.

Packaged under inert gas

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

Following reconstitution, aliquot and freeze (-20°C) each inhibitor. Each inhibitor solution is stable for up to 3 months at -20°C.

Please refer to information provided on the CD for reconstitution information of individual inhibitors.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany